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MEF2 is upregulated during cardiac hypertrophy and is required
for normal post-natal growth of the myocardium
Steven M. Kolodziejczyk, Ling Wang, Kim Balazsi, Yves DeRepentigny,
Rashmi Kothary and Lynn A. Megeney
In mammals, growth of the fetal heart is regulated by
proliferation of cardiac muscle cells. At later stages of
pre-natal life, this proliferation diminishes profoundly
[1,2] and the dramatic expansion in heart size during
the transition to adulthood is due exclusively to
hypertrophy of individual cardiomyocytes [3–5].
Cardiomyocyte hypertrophy also contributes to the
pathology of most post-natal heart disease [6–10].
Within this context, numerous signal transduction
pathways have been implicated as the link between
the effector(s) and altered cardiac gene expression
[11–16]. A common pathway has yet to be discovered,
however. Here, we found that the activity of the stress-
activated kinase p38 was enhanced in both types of
cardiomyocyte hypertrophy. We also found that a
target of the activated p38 kinase is the cardiac
transcription factor MEF2. Transgenic mice expressing
a dominant-negative form of MEF2C displayed
attenuated post-natal growth of the myocardium.
These results provide the first evidence for a single
pathway regulating both normal and pathologic
cardiomyocyte hypertrophy.
Address: Ottawa Hospital Research Institute, Ottawa Hospital
General Campus, Centre for Molecular Medicine, Ottawa, Ontario,
Canada K1H 8L6.
Correspondence: Lynn A. Megeney
E-mail: lmegeney@ogh.on.ca
Received: 23 April 1999
Revised: 4 August 1999
Accepted: 13 September 1999
Published: 11 October 1999
Current Biology 1999, 9:1203–1206
0960-9822/99/$ – see front matter 
© 1999 Elsevier Science Ltd. All rights reserved.
Results and discussion
The stress-activated kinase p38 undergoes enhanced
activation concurrent to the development of cardiomy-
ocyte hypertrophy in a murine model of dystrophy, the
mdx:MyoD–/– mouse [17]. Moreover, p38 activation leads to
cardiomyocyte hypertrophy in vitro, suggesting an impor-
tant role for this kinase in regulating post-natal growth of
the myocardium [18,19]. To discover the mechanism by
which p38 induces cardiomyocyte hypertrophy, we identi-
fied protein targets of p38 during hypertrophic growth.
Lysates from wild-type and mdx:MyoD–/– mice were sub-
jected to co-immunoprecipitation with a p38 antibody
followed by an in vitro kinase reaction. Although this
assay labeled a number of targets, one protein migrating at
approximately 53 kDa displayed an enhanced phosphate
incorporation, which increased in mdx:MyoD–/– lysates
(Figure 1a). To identify the 53 kDa protein, lysates were
subjected to a pre-immunoprecipitation with antibodies to
known p38 targets (including NFκB, MEF-2 and AP-1),
followed by the same immunoprecipitation/kinase assay
described above. Only the pre-immunoprecipitation with a
MEF2 antibody resulted in a specific reduction in the phos-
phate labeling of the 53 kDa protein, which was similar to
the reported size of MEF2 isoforms (Figure 1b,c). In
addition, mdx:MyoD–/– cardiac lysates subjected to MEF2
immunoprecipitation revealed an elevated association with
p38 (as detected by western blotting), confirming the
enhanced interaction of these proteins during hypertrophy
(data not shown).
Figure 1
MEF2 activity in heart lysates of wild-type and mdx:MyoD–/– mice. 
(a) The p38-directed phosphorylation of a 53 kDa protein, identified as
MEF2 in a pre-immunoprecipitation (pre-IP) using an anti-MEF2
antibody. Asterisk, autophosphorylated form of p38. (b) Western blot
with anti-p38 and anti-MEF2 antibodies. (c) Gel-shift assay using a
labeled MEF2 consensus oligonucleotide. The total amount of protein
used is indicated at the top. Specificity of the MEF2 complex (asterisk)
was determined by competitive inhibition with unlabeled MEF2
consensus oligonucleotide (oligo) and supershifting of the complex
with anti-MEF2 antibody (arrowhead). Similar results were obtained in
three independent experiments. 
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To examine MEF2 activity during cardiomyocyte hyper-
trophy, we performed gel mobility-shift assays using a
MEF2-binding site as a probe. Compared with wild-type
mice, heart lysates from mdx:MyoD–/– mice displayed a sig-
nificant increase in MEF2 complex formation (Figure 1c),
which is similar to the enhanced MEF2 binding reported
for pressure overload hypertrophy [20]. Consequently,
these observations suggest a role for the activated kinase
in pathologic cardiomyocyte hypertrophy. It is interesting
that members of the MEF2 family of transcription factors,
specifically MEF2A and MEF2C, have been shown to be
indispensible for regulating cardiac gene expression, and
are highly expressed in both the developing and mature
myocardium (Figure 1c; reviewed in [21]). 
As normal post-natal cardiomyocyte growth exhibits
many features common to disease hypertrophy, there
may be considerable overlap in the molecular cascades
that regulate each process. Accordingly, we investigated
the interaction between p38 kinase and MEF2 transcrip-
tion factors in the post-natal developing heart. Tyrosine
phosphorylation of p38 was elevated in lysates derived
from early-stage hearts and decreased in heart lysates of
mature animals (Figure 2a). The heart lysates from the
developmental time course were also subjected to p38
immunoprecipitation/kinase assays, which revealed a
high level of MEF2 phosphate labeling (53 kDa protein)
at early stages, declining with maturity (Figure 2b). In
addition, gel mobility-shift assays demonstrated a high
level of MEF2-binding activity for heart lysates derived
from young mice (≤ 2 weeks of age), with a substantial
reduction in activity as animals aged (Figure 2d). There-
fore, upregulation of p38/MEF2 activity occurs at devel-
opmental stages when the heart is subject to the largest
degree of cardiomyocyte hypertrophy. Interestingly, the
elevated MEF2-binding activity was concurrent to an
increased level of MEF2 proteins (Figure 2c), suggest-
ing a further synergy for p38-mediated activation of this
transcription factor.
To determine whether increased p38/MEF2 activity
was required for post-natal cardiomyocyte hypertrophy,
we generated transgenic mice that expressed a trun-
cated MEF2C protein (the carboxy-terminal transacti-
vation domain was deleted) under the control of the
α-myosin heavy chain promoter (α-MHC–MEF2C)
[13,22]. We hypothesized that removal of this region of
MEF2C, which includes the known p38-regulatable
serine and threonine residues [23,24], would result in a
loss of functional protein. Indeed, similar truncations in
MEF2A have been shown to produce a dominant-nega-
tive protein in vitro [25]. Cardiac lysates from MEF2
transgenic mice revealed a significant reduction in
MEF2–DNA complex formation (Figure 3e), which is
similar to the dominant-negative effect that has been
observed with overexpression of full-length MEF2C
containing mutations in the p38-responsive residues [23].
Thus, our observations suggest that p38-mediated phos-
phorylation of MEF2 leads to an enhanced formation of
MEF2–DNA complexes, which would directly affect
MEF2-dependent transcription.
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Figure 2
MEF2 activity in heart lysates from newborn mice and mice aged 2, 
7 and 12 weeks. (a) Immunoprecipitation (IP) with an anti-
phosphotyrosine (anti-PTyr) antibody, followed by western blotting with
anti-p38 antibody. (b) The p38-directed phosphorylation of MEF2
(53 kDa). Asterisk, autophosphorylated p38. (c) Western blotting with
anti-p38 and anti-MEF2 antibodies. (d) Gel-shift assay using a labeled
MEF2 consensus oligonucleotide. Formation of a MEF2 complex
(asterisk) remained unaffected in the presence of either a non-specific
antibody (MEK7) or a non-specific transcription factor binding site
(NFκB oligonucleotide). Similar results were obtained in three
independent experiments. The arrowhead indicates a supershift of the
complex with the anti-MEF2 antibody. 
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Table 1
Summary of α-MHC–MEF2C transgenic lines.
Transgenic line Age at death (weeks) Cardiac phenotype
1 2 (sudden) Hypoplastic
5 8 (sacrificed) Dilated/hypoplastic
15 8 (sacrificed) Mild
17 4 (sudden) Hypoplastic
22 7 (sacrificed) Mild
24 Still alive n.d.
25 Still alive n.d.
28 Still alive n.d.
30 7 (sacrificed) Dilated/hypoplastic
31 4 (sudden) Hypoplastic
37 Still alive n.d.
n.d. = not determined
Of the 11 independent founder mice that were obtained,
three died early (≤ 4 weeks of age) with severe hypoplas-
tic hearts (Figure 3b and Table 1). Histological analysis of
the affected hearts revealed a dramatic reduction in car-
diomyocyte size compared with hearts from age-matched
controls (Figure 3c,d). Examination of hearts from surviv-
ing founder mice provided further support for a hypoplas-
tic phenotype; two out of four mice had dilated ventricle
chambers while maintaining outward cardiac dimensions
similar to wild-type mice (data not shown). In addition,
hearts from affected mice displayed a significant reduc-
tion (~2–3-fold) in the expression of genes associated
with pathologic hypertrophy, such as Atrial natriuretic
factor (ANF) (Figure 3f) and α-skeletal actin (data not
shown). Thus, disruption of MEF2 activity leads to
impaired cardiomyocyte hypertrophy.
A simple interpretation of our observations suggests that
p38 activation of MEF2 proteins in the hypertrophic
heart may be specific to a p38–MEF2C interaction as,
first, the p38 immunoprecipitation/kinase assays did not
detect phosphorylation of a protein the size of MEF2A
(~68–70 kDa) and, second, the competitive inhibition of
the phosphorylated 53 kDa protein matched the known
size of MEF2C (~53 kDa). Nevertheless, MEF2A protein,
which is abundant in the adapting heart (Figure 2c), has
been shown to be a responsive target for p38-directed acti-
vation [24,26]. Moreover, the cardiac phenotype of the
MEF2C dominant-negative mouse does not exclude a
role for MEF2A. Specifically, as MEF2A and MEF2C use
a common consensus site, the underlying molecular basis
for the dominant-negative MEF2C transgene would be
equally effective in disrupting both MEF2C and MEF2A
interactions with DNA.
Taken together, our data suggest that p38 activation of
MEF2 is indispensible for precipitating the hypertrophic
response in post-natal cardiomyocytes. Importantly, this
interaction was evident in both normal and pathologic
hypertrophy, which suggests a conserved molecular mech-
anism for cardiomyocyte adaptation. Finally, the data
support the view that effective post-natal cardiac adapta-
tion may be dependent on activating multiple cardiac
transcription factors (that is, NFAT, GATA4 and MEF2),
which recapitulates the paradigm observed for develop-
mental cardiac morphogenesis [27].
Materials and methods
Histological analysis
Hearts were removed and fixed in 4% paraformaldehyde for 4–5 days,
embedded in paraffin, sectioned at 4 µm and stained with hema-
toxylin–eosin [28].
Immunoprecipitation and western blot analysis
Immunoprecipitations and western blotting from the ventricle lysates
were performed as described previously [17]. Briefly, for immunoprecipi-
tations using the pan-tyrosine-phosphorylated antibody PY20 (Trans-
duction Labs), 500 µg total protein was used with 5 µg PY20; for
immunoprecipitations using anti-p38 (Santa Cruz) or anti-MEF-2 anti-
bodies, 750 µg total protein was used with 2 µg of either anti-p38 or
anti-MEF2 antibodies; all contained 25 µl protein G–Sepharose beads
(Pharmacia). Immunoprecipitation was carried out for 16 h at 4°C. Pre-
cipitates were centrifuged, washed (3 ×) and subjected to SDS–PAGE
followed by transfer to Immobilon-P membranes (Millipore). Detection of
proteins by western blotting used the following dilutions for primary anti-
bodies: p38 and MEF-2 1:500 (Santa Cruz); secondary 1:2000.
In vitro kinase assays
Immunoprecipitations with anti-p38 antibody were performed as
described above. For MEF2 inhibition experiments, a pre-immunoprecip-
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Figure 3
Inhibited myocardial growth in mice expressing a truncated MEF2C
protein, dmMEF2C. (a,c) Wild-type and (b,d) dmMEF2C-expressing
mice. Hematoxylin–eosin stained sections of hearts (cut transversely at
mid-ventricle) revealed a substantial reduction in the size of the
myocardium in (b) 4 week old dmMEF2C mice compared with 
(a) age-matched wild-type mice. Histological comparison of hearts
revealed a marked reduction in size of individual cardiomyocytes from
(d) dmMEF2C mice compared with (c) wild-type mice of the same age
(magnification 40 ×). (e) Reduced MEF2–DNA complex formation
(asterisk) in dmMEF2C (mutant) heart lysates. (f) The decrease in ANF
gene expression in dmMEF2C (mutant) hearts was related to the
severity of the phenotype; the hypoplastic heart phenotype was visibly
more severe in mutant B than in mutant A, with a corresponding
reduction in ANF expression. The scale bars represent 1 mm in
(a,b) and 50 µm in (c,d).
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itation (3 h at 4°C) with 2 µg anti-MEF2 antibody was performed before
the p38 immunoprecipitation. Following this procedure, the precipitates
were washed twice with kinase buffer [17]. Reactions were then carried
out with 10 µCi [γ-32P]ATP in a total kinase buffer volume of 30 µl.
Reactions were allowed to proceed for 30 min at 30°C and then termi-
nated with the addition of 2 × SDS loading buffer and subjected to
SDS–PAGE. Gels were dried and exposed to film and/or subjected to
phosphoimaging to quantitate the signal.
Gel mobility-shift assays
Heart lysates were subjected to protein extraction as described above.
Briefly, 200 µg total protein lysate per sample was incubated with a
labeled ([γ-32P]ATP) MEF2 consensus oligonucleotide probe (Santa
Cruz) in the presence of 2 µg poly [dI-dC], 2 µl buffer (250 mM
HEPES, pH 7.6, 50 mM MgCl2, 340 mM KCl) in a final volume of 20 µl
for 30 min at 37°C, followed by gel electrophoresis. Competitor
oligonucleotides were added at 50-fold molar excess, while supershift
experiments were performed with 2 µg specific or non-specific antibod-
ies. Signal quantification was determined by phosphorimager analysis.
Northern analysis
Total RNA extraction and northern blotting for ANF detection were
performed as described previously [29].
Transgenic mice
A MEF2C construct encoding amino acids 1–95 was produced by PCR
amplification using primers corresponding to the required 5′ and 3′
regions. To direct post-natal cardiac-specific expression of the MEF2C
construct, the sequence-verified PCR product was cloned into an expres-
sion vector containing the α-MHC promoter [22]. The fusion vector was
then digested with BamHI, and the α-MHC–MEF2C transgene was gel-
purified and eluted in oocyte injection buffer. Injection and derivation of
transgenic mice were performed as described [30].
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